Commentary|Articles|November 22, 2026

Cemiplimab Response Tied to Longer Quality-of-Life Benefit in aNSCLC

Listen
0:00 / 0:00

In this Q&A, Konstantin Dmitrievich Penkov, MD, discusses delayed quality-of-life decline with cemiplimab plus chemotherapy in aNSCLC.

At the European Society for Medical Oncology (ESMO) 2026 Congress, held October 23 to 27 in Madrid, Spain, lead investigator Konstantin Dmitrievich Penkov, MD, presented his poster, “Impact of Objective Response on PROs in Patients Receiving Cemiplimab/Chemotherapy vs Chemotherapy for aNSCLC: EMPOWER-Lung 3 Part 2.”1

Cemiplimab (Libtayo; Regeneron) received FDA approval on February 22, 2021, as monotherapy for the first-line treatment of patients with advanced non–small cell lung cancer (aNSCLC) whose tumors have high PD-L1 expression and no EGFR, ALK, or ROS1 aberrations.2 On November 8, 2022, the agency approved cemiplimab in combination with platinum-based chemotherapy for the first-line treatment of patients with aNSCLC without EGFR, ALK, or ROS1 aberrations, regardless of PD-L1 expression.3

Following the meeting, in an interview with The American Journal of Managed Care® (AJMC®), Penkov discussed post hoc analyses of the EMPOWER-Lung 3 Part 2 trial (NCT03409614), which found that first-line cemiplimab plus chemotherapy delayed quality-of-life deterioration in aNSCLC.1 Building on these findings, the analyses showed that achieving an objective response translated into a longer time to deterioration only in patients who received cemiplimab.

This transcript has been lightly edited for clarity.

AJMC: For context, can you summarize the key initial findings from the EMPOWER-Lung 3 Part 2 trial?

Penkov: It's a trial of cemiplimab, an immunotherapy agent added to a platinum doublet in patients with aNSCLC. We found that median overall survival was 21.9 months for cemiplimab plus chemotherapy vs 13 months for chemotherapy alone.

We saw similar results in progression-free survival. The cemiplimab group had better results for progression-free survival. The objective response rate was also better in the cemiplimab arm than in the chemotherapy-only arm.

AJMC: Building on those results, what were the primary objectives of the post hoc analyses presented at this year's ESMO Congress, and what methods did you use to investigate them?

Penkov: About methods, the patient-reported outcomes were assessed at baseline on day 1 and then at the start of each 3-week treatment cycle for the first 6 doses. Then, we evaluated patient-reported outcomes every 3 cycles. We used the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30, also known as the EORTC QLQ-C30, and the EORTC QLQ-Lung Cancer Module, or the EORTC QLQ-LC13.

These questionnaires were used in this trial. We included a longitudinal mixed-effects model comparing treatment arms and time to definitive clinically meaningful deterioration (TTD). These analyses were performed for global health status/quality of life. All scales from these questionnaires were compared for TTD. Comparisons were made using the stratified log-rank test and the proportional hazards model.

The conclusion we have is that cemiplimab plus chemotherapy resulted in significant overall improvement in pain symptoms and delayed TTD. So, patients who received cemiplimab had longer periods before deterioration.

AJMC: Can you summarize the main findings from these analyses? Were there any that surprised you?

Penkov: It wasn't surprising, because we understand that patients who have better results have better quality of life. But to evaluate how objective response affected patient-reported outcomes in this trial, we performed an exploratory analysis of patients with and without objective response, looking at both treatment arms combined and each arm separately.

We saw interesting results. In patients who received cemiplimab, achieving an objective response translated into a longer TTD. In patients who received chemotherapy alone, we didn’t see a statistically meaningful difference. Objective response in those patients was still good, but it didn’t translate into a longer TTD; that’s what we understand from the results now.

AJMC: What do these findings mean for payers and health systems assessing the value of first-line chemoimmunotherapy beyond survival and response rates?

Penkov: Beyond improving overall survival, achieving an objective response rate is important and is a goal for improving quality of life in patients with aNSCLC. In particular, achieving an objective response after being treated with cemiplimab plus chemotherapy as a first-line therapy in NSCLC may lead to improved quality-of-life outcomes.

AJMC: Looking ahead, what further research is needed in this area?
Penkov:
We will expand this research to look at all functional and symptom scales, including but not limited to chest pain and dyspnea. Of course, we are using quality-of-life measures, and this will be the next step in our work.

References

  1. Penkov KD, Baramidze A, Makharadze T, et al. Impact of objective response on PROs in patients receiving cemiplimab/chemotherapy vs chemotherapy for aNSCLC: EMPOWER-lung 3 part 2. Presented at: ESMO 2026 Congress; October 23-27, 2026; Madrid, Spain. https://oncologypro.esmo.org/congress-resources/esmo-congress-2026?presentation=impact_of_objective_response_on_pros_in_patients_r
  2. McNulty R. FDA approves cemiplimab for first-line advanced NSCLC with PD-L1 expression. AJMC. February 22, 2021. Accessed November 18, 2026. https://www.ajmc.com/view/fda-approves-cemiplimab-for-first-line-advanced-nsclc-with-pd-l1-expression
  3. Inserro A. FDA approves cemiplimab plus chemotherapy as first-line NSCLC treatment. AJMC. November 8, 2022. Accessed November 18, 2026. https://www.ajmc.com/view/fda-approves-cemiplimab-plus-chemotherapy-as-first-line-nsclc-treatment

Related to this article